Kashani-Sabet M, Funato T, Florenes V A, Fodstad O, Scanlon K J
Department of Medical Oncology, City of Hope National Medical Center, Duarte, California 91010.
Cancer Res. 1994 Feb 15;54(4):900-2.
In this study, the efficacy of an anti-ras ribozyme in reversing the neoplastic phenotype was investigated. Murine NIH3T3 cells were transfected with cellular DNA from the FEMX-I human melanoma cell line expressing the activated H-ras gene. The transformed cells displayed the neoplastic phenotype in vitro and were tumorigenic in nude mice in vivo. When the transformants were transfected by a ribozyme designed to cleave only activated H-ras RNA, the transformed phenotype was abrogated. In contrast, expression of a mutant ribozyme, essentially acting only as antisense, into the transformed cells resulted in less dramatic changes in cell growth and tumorigenicity. These results reinforce the potential role of anti-oncogene ribozymes as suppressors of neoplastic growth, with possible implications for gene therapy.
在本研究中,研究了一种抗ras核酶在逆转肿瘤表型方面的功效。用来自表达活化H-ras基因的FEMX-I人黑色素瘤细胞系的细胞DNA转染小鼠NIH3T3细胞。转化后的细胞在体外表现出肿瘤表型,在体内裸鼠中具有致瘤性。当用设计用于仅切割活化H-ras RNA的核酶转染转化体时,转化表型被消除。相比之下,将基本上仅作为反义作用的突变核酶表达到转化细胞中,导致细胞生长和致瘤性的变化不那么显著。这些结果强化了抗癌基因核酶作为肿瘤生长抑制剂的潜在作用,可能对基因治疗有影响。